Switch theme
Sign up to access all valuation multiples
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
1976
3.1K+
LTM Revenue $1.2B
LTM EBITDA $419M
$7.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bio-Techne has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $419M.
In the most recent fiscal year, Bio-Techne achieved revenue of $1.2B and an EBITDA of $313M.
Bio-Techne expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bio-Techne valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $835M | XXX | $770M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $419M | XXX | $313M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $383M | XXX | $243M | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $302M | XXX | $168M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $167M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bio-Techne's stock price is $48.
Bio-Techne has current market cap of $7.6B, and EV of $7.9B.
See Bio-Techne trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.9B | $7.6B | XXX | XXX | XXX | XXX | $1.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bio-Techne has market cap of $7.6B and EV of $7.9B.
Bio-Techne's trades at 6.6x EV/Revenue multiple, and 21.5x EV/EBITDA.
Equity research analysts estimate Bio-Techne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Techne has a P/E ratio of 25.1x.
See valuation multiples for Bio-Techne and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.6B | XXX | $7.6B | XXX | XXX | XXX |
| EV (current) | $7.9B | XXX | $7.9B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 18.8x | XXX | 21.5x | XXX | XXX | XXX |
| EV/EBIT | 20.5x | XXX | 25.1x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.1x | XXX | 32.2x | XXX | XXX | XXX |
| EV/FCF | 34.6x | XXX | 34.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBio-Techne's last 12 month revenue growth is 6%
Bio-Techne's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Bio-Techne's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Techne's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bio-Techne and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Techne acquired XXX companies to date.
Last acquisition by Bio-Techne was XXXXXXXX, XXXXX XXXXX XXXXXX . Bio-Techne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bio-Techne founded? | Bio-Techne was founded in 1976. |
| Where is Bio-Techne headquartered? | Bio-Techne is headquartered in United States of America. |
| How many employees does Bio-Techne have? | As of today, Bio-Techne has 3.1K+ employees. |
| Who is the CEO of Bio-Techne? | Bio-Techne's CEO is Mr. Kim Kelderman. |
| Is Bio-Techne publicy listed? | Yes, Bio-Techne is a public company listed on NAS. |
| What is the stock symbol of Bio-Techne? | Bio-Techne trades under TECH ticker. |
| When did Bio-Techne go public? | Bio-Techne went public in 1992. |
| Who are competitors of Bio-Techne? | Similar companies to Bio-Techne include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Bio-Techne? | Bio-Techne's current market cap is $7.6B |
| What is the current revenue of Bio-Techne? | Bio-Techne's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Bio-Techne? | Bio-Techne revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Bio-Techne? | Current revenue multiple of Bio-Techne is 6.5x. |
| Is Bio-Techne profitable? | Yes, Bio-Techne is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bio-Techne? | Bio-Techne's last 12 months EBITDA is $419M. |
| What is Bio-Techne's EBITDA margin? | Bio-Techne's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Bio-Techne? | Current EBITDA multiple of Bio-Techne is 18.8x. |
| What is the current FCF of Bio-Techne? | Bio-Techne's last 12 months FCF is $228M. |
| What is Bio-Techne's FCF margin? | Bio-Techne's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Bio-Techne? | Current FCF multiple of Bio-Techne is 34.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
